|
|
|
|
|
02.09.25 - 13:33
|
Cybin Announces Senior Leadership Changes (Business Wire)
|
|
|
Doug Drysdale to step down as Chief Executive Officer; Eric So appointed Interim Chief Executive Officer
This news release constitutes a “designated news release” for the purposes of Cybin's prospectus supplement dated February 10, 2025, to its short form base shelf prospectus dated August 17, 2023, as amended December 22, 2023, April 8, 2024, and January 6, 2025.TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe Canada:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, announced that, effective September 2, 2025, Doug Drysdale will step down as the Company's Chief Executive Officer. The Company's Co-Founder and President, Eric So, has been appointed as Interim Chief Executive Officer by the Board of Directors.
“Cybin was founded with a singular mission: to transform the treatment paradigm for mental health. With a solid f...
|
|
|
18.08.25 - 23:36
|
Cybin Announces Results of Annual Meeting of Shareholders (Business Wire)
|
|
|
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the voting results for each of the matters presented at the Company's annual meeting of shareholders held on August 18, 2025 (the “Meeting”). There were 90 shareholders represented in person or by proxy at the Meeting holding 11,264,212 common shares, representing 48.92% of Cybin's total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are set out below:
1. Appointment of Auditor
Zeifmans LLP was appointed auditor of Cybin until the next annual meeting of shareholders at renumeration to be fixed by the directors of Cybin. Voting results are set out below:
Votes For
Votes Withheld
#
%
#
%
11,206,201
99.485
58,010
0.515%
2. ...
|
|
|
|
|
13.08.25 - 23:36
|
Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results (Business Wire)
|
|
|
Cybin continues to make significant progress on its journey to bring breakthrough therapies to patients by delivering on the following key milestones
- Received European and United Kingdom Medical and Healthcare Products Regulatory Agency (“MHRA”) approval for EMBRACE, the Company's second pivotal study evaluating CYB003 for the adjunctive treatment of Major Depressive Disorder (“MDD”) on schedule -
- EMBRACE study to enroll 330 participants at approximately 60 clinical sites across the United States, United Kingdom, Europe, and Australia1 -
- Completion of patient enrollment in CYB004 Phase 2 study in General Anxiety Disorder expected in August 20251 -
- Recent financing agreement of US$50 million principal amount of convertible debentures will advance clinical pipeline programs -
- Cash totaled US$118.7 million as of June 30, 2025 -
This news release constitutes a “designated news release” for the purposes of Cybin's prospectus supplement dated February 10, 2025, to its short form ...
|
|
|
|
|
01.07.25 - 17:21
|
REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures (Business Wire)
|
|
|
- Funding agreement contemplates a conversion formula with a potential 30% premium upon conversion and positions the Company for growth, and accelerated advancement of its clinical pipeline programs, CYB003 and CYB004 -TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American: CYBN) (Cboe Canada: CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the Company has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with High Trail Special Situations LLC (“High Trail”), pursuant to which the Company agreed to sell and issue to High Trail up to US$500,000,000 in aggregate principal amount of unsecured convertible debentures (the “Convertible Debentures”). The sale and issue of US$50,000,000 principal amount of Convertible Debentures was completed on June 30, 2025 (the “Private Placement”)....
|
|
|
|
|
01.07.25 - 04:06
|
Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights (Business Wire)
|
|
|
- Dosing is underway in the Phase 3 CYB003 PARADIGM program which comprises two 12-week randomized, double-blind, placebo-controlled studies (APPROACH™ and EMBRACE™) and a long-term extension study (EXTEND), with anticipated combined enrollment of approximately 550 patients1 -
- Strengthened commercial preparations and manufacturing capabilities through partnerships with Osmind and Thermo Fisher Scientific, respectively -
- APPROACH expects to enroll 220 participants at approximately 45 clinical sites across the United States1 -
- Initiation of second CYB003 pivotal study EMBRACE and completion of CYB004 Phase 2 study in general anxiety disorder expected around mid-20251 -
- Cash totaled C$135 million as of March 31, 2025 -
This news release constitutes a “designated news release” for the purposes of Cybin's prospectus supplement dated February 10, 2025, to its short form base shelf prospectus dated August 17, 2023, as amended December 22, 2023, April 8, 2024, and January 6, 2025.TORONTO--(BUSINE...
|
|
|
01.07.25 - 03:30
|
Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures (Business Wire)
|
|
|
- Funding agreement contemplates a conversion formula with a potential 30% premium upon conversion and positions the Company for growth, and accelerated advancement of its clinical pipeline programs, CYB003 and CYB004 -TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American: CYBN) (Cboe Canada: CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the Company has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with High Trail Special Situations LLC (“High Trail”), pursuant to which the Company agreed to sell and issue to High Trail up to US$500,000,000 in aggregate principal amount of unsecured convertible debentures (the “Convertible Debentures”). The sale and issue of US$50,000,000 principal amount of Convertible Debentures was completed on June 30, 2025 (the “Private Placement”)....
|
|
|
|
|
|
|
20.05.25 - 13:33
|
Cybin Applauds FDA Commissioner Dr. Martin Makary′s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics (Business Wire)
|
|
|
- U.S. Food and Drug Administration (“FDA”) Commissioner identifies psychedelic drug development as a top agency priority in an effort to address unmet needs in mental health -
- Calls for FDA to be open to innovative treatments that show promise, even when they challenge traditional understanding of medicine -
- CYB003 granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder (“MDD”) -
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, applauds recent comments made by Dr. Martin Makary, Commissioner of the U.S. FDA relating to the importance of accelerating and prioritizing research on the clinical benefits of psychedelic therapeutics.
“It is gratifying that the FDA Commissioner shares our belief in the potential therape...
|
|
|
|
|
|
|
|
|
|
|
|
|
11.02.25 - 03:51
|
Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights (Business Wire)
|
|
|
- Launched strategic clinical site partnerships to accelerate PARADIGM, a multinational pivotal Phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder (“MDD”) -
- PARADIGM comprises two 12-week randomized, double-blind, placebo-controlled studies (APPROACH™ and EMBRACE™) and a long-term extension study (EXTEND), with anticipated combined enrollment of approximately 550 patients -
- APPROACH has been initiated and will enroll 220 participants at more than 40 clinical sites in the United States and Europe -
- Upcoming milestones include topline efficacy data readout from CYB004 Phase 2 study in general anxiety disorder and initiation of EXTEND and EMBRACE pivotal studies of CYB003 around mid-year 2025 -
- CYB003 in development for MDD has a total addressable market of >300 million people worldwide2-
- Cash totaled C$136.3 million as of December 31, 2024 -
This news release constitutes a “designated news release” for the purposes of Cybin's prospectus supplem...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
